Factors associated with statin selection among privately insured commercial and Medicare patients

References

• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
   PubMed Web of Science ®Google Scholar
• Mason RP. Molecular basis of differences among statins and a comparison of antioxidant vitamins. Am J Cardiol 2006;98:34-41P
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program. National Heart, Lung, and Blood Institute. National Institutes of Health. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. NIH Publication No. 02-5215. September 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm [Last accessed 10 January 2013]
   Google Scholar
• Alagona P Jr. Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evidence 2010;5:91-105
   PubMedGoogle Scholar
• Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59
   PubMed Web of Science ®Google Scholar
• Meade LT. Barriers to achieving LDL cholesterol goals. US Pharm 2007;32:66-71
   Google Scholar
• Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med 2007;22:391-5
   PubMed Web of Science ®Google Scholar
• Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008;14:9-15
   PubMedGoogle Scholar
• Ivanova J, Frois C, Bae J, et al. Low-density lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: a chart extraction-based approach. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress, Madrid, Spain, November 5–8, 2011
   Google Scholar
• Zhao Z, Ivanova J, Bae J, et al. Factors associated with failing to achieve low-density lipoprotein cholesterol goal at 12 months with existing statin therapy: a chart extraction-based approach. Poster presented at the ISPOR 14th Annual European Congress, Madrid, Spain, November 5–8, 2011
   Google Scholar
• Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
   PubMed Web of Science ®Google Scholar
• Gruer PJK, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811-15
   PubMed Web of Science ®Google Scholar
• Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Rep 2000;1:14-19
   Google Scholar
• Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Safety 2005;28:263-75
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III-50-7
   Google Scholar
• Hickmott H, Wynne H, and Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003;89:949-50
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010;123:151-7
   PubMed Web of Science ®Google Scholar
• Simonson SG, Martin, PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005;45:927-34
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106
   PubMed Web of Science ®Google Scholar
• Yu CY, Campbell SE, Zhu B, et al. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin 2012;28:187-94
   PubMed Web of Science ®Google Scholar
• Hulgan T, Sterling TR, Daugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005;38:277-82
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. March 1, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm [Last accessed 10 January 2013]
   Google Scholar
• Truven Health Analytics Inc. Data, databases, and online tools. Available at: http://www.truvenhealth.com/your_healthcare_focus/pharmaceutical_and_medical_device/data_databases_and_online_tools.aspx [Last accessed 4 October 2011]
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent health care costs, and cardiovascular hospitalizations. Am J Cardiol 2011;107:1662-6
   PubMed Web of Science ®Google Scholar
• Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-44
   PubMed Web of Science ®Google Scholar